Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.43 |
| ▸ | COMT | P21964 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32669579 | 0.89 | FTO (0.49) | KMT2AMEN1FTOCOMTMAPT | |
| SCHEMBL32670122 | 0.88 | FTO (0.45) | KMT2AMEN1FTOCOMTEGFR | |
| SCHEMBL32669627 | 0.85 | FTO (0.43) | KMT2AMEN1FTOCOMTMAPT | |
| SCHEMBL32669918 | 0.84 | FTO (0.42) | KMT2AMEN1FTOCOMTEGFR | |
| SCHEMBL32670057 | 0.84 | KMT2A (0.47) | KMT2AMEN1FTOCOMTMAPT | |
| SCHEMBL32669870 | 0.84 | FTO (0.53) | KMT2AMEN1FTOCOMTMAPT | |
| SCHEMBL32669871 | 0.84 | FTO (0.51) | KMT2AMEN1FTOCOMTMAPT | |
| SCHEMBL32669778 | 0.83 | FTO (0.47) | KMT2AMEN1FTOCOMTMAPT | |
| SCHEMBL32670048 | 0.82 | SMN1; SMN2 (0.41) | KMT2AMEN1MAPTSMN1; SMN2 | |
| SCHEMBL32669671 | 0.82 | FTO (0.46) | KMT2AMEN1FTOCOMTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035341-A1 | FTO INHIBITORS | RPXDS CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035341-A1 | FTO INHIBITORS | FTO, LDLR, GPR119 | KMT2A 567/4885MEN1 3974/4885FTO 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.